U.S. markets close in 2 hours 5 minutes
  • S&P 500

    3,280.11
    +33.52 (+1.03%)
     
  • Dow 30

    27,010.25
    +194.81 (+0.73%)
     
  • Nasdaq

    10,845.34
    +173.07 (+1.62%)
     
  • Russell 2000

    1,469.27
    +17.45 (+1.20%)
     
  • Crude Oil

    40.23
    -0.08 (-0.20%)
     
  • Gold

    1,868.50
    -8.40 (-0.45%)
     
  • Silver

    23.16
    -0.04 (-0.18%)
     
  • EUR/USD

    1.1628
    -0.0048 (-0.41%)
     
  • 10-Yr Bond

    0.6590
    -0.0070 (-1.05%)
     
  • GBP/USD

    1.2715
    -0.0036 (-0.29%)
     
  • USD/JPY

    105.5900
    +0.1880 (+0.18%)
     
  • BTC-USD

    10,711.48
    -49.11 (-0.46%)
     
  • CMC Crypto 200

    228.48
    +10.65 (+4.89%)
     
  • FTSE 100

    5,842.67
    +19.89 (+0.34%)
     
  • Nikkei 225

    23,204.62
    +116.80 (+0.51%)
     

RapidAI Receives FDA Clearance of Rapid LVO For Identification of Suspected Large Vessel Occlusions

RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid LVO has received Food and Drug Administration (FDA) clearance for detecting suspected LVOs (Large Vessel Occlusions).

Rapid LVO helps physicians speed up triage or transfer decision-making. Working in as few as 3 minutes, Rapid LVO uses a vessel tracker in conjunction with assessment of brain regions with reduced blood vessel density to identify suspected LVOs with a sensitivity of 97% and a specificity of 96%. Stroke team members are also immediately notified when a suspected LVO is detected.

"LVOs are the most disabling and deadly ischemic strokes," said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of RapidAI. "The ability to identify LVOs rapidly facilitates more effective treatment. This is why we are very excited about the FDA clearance of Rapid LVO, a significant step forward in stroke diagnostics and care."

RapidAI makes the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. Rapid® is the only clinically validated platform available and considered by many to be the gold standard for advanced cerebrovascular imaging.

To learn more visit www.RapidAI.com.

About RapidAI

RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1,000,000 scans from more than 1,600 hospitals in over 50 countries, the Rapid® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview®, a comprehensive aneurysm management platform.

RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit RapidAI.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200813005190/en/

Contacts

Peter Evers
Natron Communications for RapidAI
(415) 524-8899
pr@RapidAI.com